Price T Rowe Associates Inc Cue Biopharma, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding CUE
# of Institutions
77Shares Held
13.8MCall Options Held
56.1KPut Options Held
11.1K-
Bleichroeder LP New York, NY2.86MShares$2.17 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$1.83 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$1.54 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$575,1190.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny494KShares$375,4300.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $26.9M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...